Trial · NCT07391761
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | rwTTR (real-world time to response) | At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.) | Time from index date to the first documented real-world response. |
| Primary | rwORR (real-world overall response rate) | At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.) | Proportion of patients achieving real-world overall response at predefined assessment time points. |
| Primary | rwDOR (real-world duration of response） | From first response until 18 months | Time from the first documented real-world response to real-world disease progression, death, or end of study. |
| Primary | rwPFS (real-world progression-free survival) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to the first documented real-world disease progression or death. |
| Primary | rwOS (real world overall survival) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to death from any cause. |
| Primary | rwTTNT (real world time to next treatment) | From initiation of elranatamab treatment (index date) until 18 months | Time from index date to initiation of the next line of anti-myeloma therapy or end of study. |
| Secondary | Demographic: Age | At baseline | Age (measured in years) |
| Secondary | Demographic: Sex | From MM diagnosis until index date, and from index date until 18 months | sex/gender (male/female) |
| Secondary | Anthropometric Measures | At baseline | Height (in cm), weight (in kg), BMI (kg/m²), |
| Secondary | ECOG Performance Status | At baseline | Number and proportion of patients in each ECOG PS category (0-5) |
| Secondary | Myeloma-related Clinical Characteristics | At baseline | Baseline disease characteristics including myeloma type (IgG, non-IgG, light-chain, non-secretory), bone marrow plasma cell %, presence of EMD, ECOG status, CRAB symptoms, ISS/R-ISS stage, MGUS, SMM, and cytogenetic risk. |
| Secondary | Laboratory Characteristics | At baseline | Baseline laboratory result of creatinine clearance (CrCl) categories (stages 1-5 or \<30/≥30 mL/min) |
| Secondary | Prior Treatment History | At baseline | Number and proportion of patients with prior ASCT, prior anti-MM therapies |
| Secondary | Time from Diagnosis and Line of Elranatamab Treatment | From the index date (initiation of elranatamab treatment) up to 18 months | Time from MM diagnosis to elranatamab initiation. |
| Secondary | Elranatamab Discontinuation and Treatment Modifications | From the index date (initiation of elranatamab treatment) up to 18 months | Number and proportion of patients with treatment discontinuation (and reasons), dosing or schedule modifications (excluding step-up), and switches from QW to Q2W after 6 cycles. |
| Secondary | Subsequent Treatments After Progression | From the index date (initiation of elranatamab treatment) up to 18 months | Number and proportion of patients receiving subsequent treatments following first progression or discontinuation of elranatamab. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07391761/registered